Abivax Presents First Half 2025 Financial Results
PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30, 2025. The interim financial statements for the first half of 2025, approved by the Company’s Board of Directors on September 4, 2025, have been reviewed by the Company’s external auditors.
Abivax provided the following key updates on its business and operational goals in press releases published:
- On June 11, 2025, a press release titled “Abivax Announces Results of its June 6, 2025 Annual General Meeting”
- On July 22, 2025, a press release titled “Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis”
- On July 28, 2025, a press release titled “Abivax Announces Closing of $747.5 Million Public Offering”
First Half 2025 Financial Highlights (IFRS figures)
(Consolidated, unaudited results)
| Income Statement | Six months ended June 30, |
Change | |||
| in millions of euros | 2025 | 2024 | |||
| Total operating income | 2.1 | 6.8 | (4.7) | ||
| Total operating expenses | |||||
| of which Research and Development costs | (77.9) | (64.7) | (13.2) | ||
| of which Sales and Marketing costs | (1.5) | (4.2) | 2.7 | ||
| of which General and Administrative costs | (16.3) | (17.9) | 1.6 | ||
| Operating loss | (93.7) | (80.0) | (13.7) | ||
| Financial (loss) | (7.1) | (1.6) | (5.5) | ||
| Net loss for the period | (100.8) | (81.6) | (19.2) | ||
| Balance Sheet | June 30, 2025 | December 31, 2024 | Change | ||
| in millions of euros | |||||